{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T05:14:02Z","timestamp":1700284442738},"reference-count":31,"publisher":"Japanese Society of Internal Medicine","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,11,15]]},"DOI":"10.2169\/internalmedicine.1006-22","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T22:25:14Z","timestamp":1680215114000},"page":"3321-3326","source":"Crossref","is-referenced-by-count":0,"title":["Factors Influencing the Indeterminate Results in a T-SPOT.&lt;i&gt;TB&lt;\/i&gt; test: A Matched Case-control Study"],"prefix":"10.2169","volume":"62","author":[{"given":"Yoriko","family":"Herai","sequence":"first","affiliation":[{"name":"Division of Infection Control, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misuzu","family":"Yahaba","sequence":"additional","affiliation":[{"name":"Division of Infection Control, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshibumi","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Division of Infection Control, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Murata","sequence":"additional","affiliation":[{"name":"Division of Laboratory Medicine, Chiba University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Chiba","sequence":"additional","affiliation":[{"name":"Division of Infection Control, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Igari","sequence":"additional","affiliation":[{"name":"Division of Infection Control, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. World Health Organization. Tuberculosis [Internet]. [cited 2022 Mar 1]. Available from: https:\/\/www.who.int\/health-topics\/tuberculosis#tab=tab_1"},{"key":"2","unstructured":"2. World Health Organization. The top 10 causes of death [Internet]. [cited 2022 Mar 1]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death"},{"key":"3","unstructured":"3. Centers for Disease Control and Prevention. Latent TB infection and TB disease [Internet]. [cited 2022 Mar 1]. Available from: https:\/\/www.cdc.gov\/tb\/topic\/basics\/tbinfectiondisease.htm"},{"key":"4","unstructured":"4. World Health Organization. Latent tuberculosis infection [Internet]. [cited 2022 Mar 1]. Available from: https:\/\/www.who.int\/tb\/publications\/2018\/executivesummary_consolidated_guidelines_ltbi.pdf?ua=1"},{"key":"5","unstructured":"5. Mazurek GH, Jereb J, Vernon A, et al.; Centers for Disease Control and Prevention. Updated guidelines for using interferon gamma release assays to detect <i>Mycobacterium tuberculosis<\/i> infections - United States, 2010. MMWR 59: 1-25, 2010."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sun X, Wan S, Zhang L, Zhang Y, Liu X. Prevalence and influencing factors of the high nil-control spot count in T-SPOT.<i>TB<\/i>: a matched case-control study. Clin Chim Acta 487: 96-100, 2018.","DOI":"10.1016\/j.cca.2018.09.012"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kobashi Y, Sugiu T, Shimizu H, et al. Clinical evaluation of the T-SPOT.<i>TB<\/i> test for patients with indeterminate results on the QuantiFERON TB-2G test. Intern Med 48: 137-142, 2009.","DOI":"10.2169\/internalmedicine.48.1432"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lee YM, Kim SM, Park SJ, et al. Indeterminate T-SPOT.<i>TB<\/i> test results in patients with suspected extrapulmonary tuberculosis in routine clinical practice. Infect Chemother 45: 44-50, 2013.","DOI":"10.3947\/ic.2013.45.1.44"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Chen J, Sun J, Zhang R, et al. T-SPOT.<i>TB<\/i> in the diagnosis of active tuberculosis among HIV-infected patients with advanced immunodeficiency. AIDS Res Hum Retroviruses 27: 289-294, 2011.","DOI":"10.1089\/aid.2010.0062"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Santin M, Munoz L, Rigau D. Interferon-\u03b3 release assays for the diagnosi of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. PLoS One 7: e32482, 2012.","DOI":"10.1371\/journal.pone.0032482"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ciappini E, Bonsignori F, Accetta G, et al. Interferon-\u03b3 release assays for the diagnosis of <i>Mycobacterium tuberculosis<\/i> infect in children: a literature review. Int J Immunopathol Pharmacol 25: 335-343, 2012.","DOI":"10.1177\/039463201202500203"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lagrange PH, Herrmann JL. Diagnosing latent tuberculosis infection in the HIV era. Open Respir Med J 2: 52-59, 2008.","DOI":"10.2174\/1874306400802010052"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Meier NR, Volken T, Geiger M, Heininger U, Tebruegge M, Ritz N. Risk factors for indeterminate interferon-gamma release assay for the diagnosis of tuberculosis in children - a systematic review and meta-analysis. Front Pediatr 7: 208, 2019.","DOI":"10.3389\/fped.2019.00208"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Elzi L, Steffen I, Furrer H, et al. Improved sensitivity of an interferon-gamma release assay (T-SPOT.<i>TB<\/i>\u2122) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection. BMC Infect Dis 11: 319, 2011.","DOI":"10.1186\/1471-2334-11-319"},{"key":"15","unstructured":"15. Oxford Immunotec. Package insert foe <i>in vitro<\/i> diagnostic use [Internet]. [cited 2022 Mar 1]. Available from: http:\/\/www.oxforddiagnosticlaboratories.eu\/wp-content\/media\/PI-TB-IVD-UK-v3.pdf"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kanda Y. Investigation of the freely available easy-to-use software &apos;EZR&apos; for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Umekita K, Hashiba Y, Iwao K, et al. Human T-cell leukemia virus type 1 may invalidate T-SPOT.<i>TB<\/i> assay results in rheumatoid arthritis patients: a retrospective case-control observational study. PLoS ONE 15: e0233159, 2020.","DOI":"10.1371\/journal.pone.0233159"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Mandalakas AM, Highsmith HY, Harris NM, Pawlicka A, Kirchner HL. T-SPOT.<i>TB<\/i> performance in routine pediatric practice in a low TB burden setting. Pedatr Infect Dis J 37: 292-297, 2018.","DOI":"10.1097\/INF.0000000000001792"},{"key":"19","unstructured":"19. Walsh MC, Camerlin AJ, Miles R, et al. The sensitivity of interferon-\u03b3 release assays is not compromised in tuberculosis patients with diabetes. Int J Tuberc Lung Dis 15: 179-184, i-iii, 2001."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Stalenhoef JE, Alisjahbana B, Nelwan EJ, et al. The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus. Eur J Clin Microbil Infect Dis 27: 97-103, 2008.","DOI":"10.1007\/s10096-007-0395-0"},{"key":"21","unstructured":"21. Tsukaguchi K, Okamura H, Ikuno M, et al. The relation between diabetes mellitus and IFN-gamma, IL-12 and IL-10 productions by CD4<sup>+<\/sup> alpha beta T cells and monocytes in patients with pulmonary tuberculosis. Kekkaku 72: 617-622 (in Japanese)."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Restrepo BI, Fisher-Hoch SP, Pino PA, et al. Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells. Clin Infect Dis 47: 634-641, 2008.","DOI":"10.1086\/590565"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Calcagni E, Elenkov I. Stress system activity, innate and T helper cutokines, and susceptibity to immune-related diseases. Ann Y Acad Sci 1069: 62-76, 2006.","DOI":"10.1196\/annals.1351.006"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Rodriguez L, Gonzalez C, Flores L, Zamudio LJ, Graniel J, Ortiz R. Assessment by flow cytometry of cytokine production in malnourished children. Clin Diagn Lab Immunol 12: 502-507, 2005.","DOI":"10.1128\/CDLI.12.4.502-507.2005"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Yamano Y, Araya N, Sato T, et al. Abnormally high levels of virus-infected IFN-\u03b3<sup>+<\/sup>CCR4<sup>+<\/sup>CD4<sup>+<\/sup>CD25<sup>+<\/sup>Tcells in a retrovirus-associated neuroinflammatory disorder. PLos ONE 4: e6517, 2009.","DOI":"10.1371\/journal.pone.0006517"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Futsch N, Prates G, Mahieux R, Casseb J, Dutartre H. Cytokine networks dysregulation during HTLV-1 infection and associated diseases. Viruses 10: 691, 2018.","DOI":"10.3390\/v10120691"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Welles SL, Tachibana N, Okayama A, et al. Decreased reactivity to PPD among HTLV-1 carriers in relation to virus and hematologic status. Int J Cancer 56: 337-340, 1994.","DOI":"10.1002\/ijc.2910560307"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Tachibana N, Okayama A, Ishizaki J, et al. Suppression pf tuberculin skin reaction in healthy HTLV-1 carriers from Japan. Int J Cancer 42: 829-831, 1988.","DOI":"10.1002\/ijc.2910420605"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Araya N, Sato T, Ando H, et al. HTLV-1 induces a Th1-like state in CD4+CCR4+T cells. J Clin Invest 124: 3431-3442, 2014.","DOI":"10.1172\/JCI75250"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Souaz A, Carcalho N, Neves Y, et al. Association of tuberculosis status with nerologic diseases and immune response in HTLV-1 infection. AIDS Res Hum Retroviruses 33: 1126-1133, 2017.","DOI":"10.1089\/aid.2015.0340"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 3: 388, 2012.","DOI":"10.3389\/fmicb.2012.00388"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/22\/62_1006-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T03:21:32Z","timestamp":1700277692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/22\/62_1006-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":31,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1006-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,15]]},"article-number":"1006-22"}}